Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.75% |
| 2 | Technology | 13.74% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 11.51% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
LSI Industries
LYTS
$913M
| $2.3M | ﹤0.01% |
236,200
+10,200
| +5% | +$100K |
|
|
INFI
2152
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $2.29M | ﹤0.01% |
1,700,000
-160,900
| -9% | -$210K |
|
|
DM
2153
DELISTED
Dominion Energy Midstream Ptr LP
DM
| $2.29M | ﹤0.01% |
77,444
-62,456
| -45% | -$1.61M |
|
2154
Wingstop
WING
$3.44B
| $2.28M | ﹤0.01% |
77,200
-76,458
| -50% | -$2.25M |
|
|
ALTA
2155
DELISTED
Altabancorp
ALTA
| $2.28M | ﹤0.01% |
84,900
+41,400
| +95% | +$926K |
|
|
NEWR
2156
DELISTED
New Relic, Inc.
NEWR
| $2.27M | ﹤0.01% |
+80,362
| New | +$2.65M |
|
2157
Adecoagro
AGRO
$1.29B
| $2.27M | ﹤0.01% |
218,500
+158,300
| +263% | +$1.7M |
|
2158
Helix Energy Solutions
HLX
$1.54B
| $2.27M | ﹤0.01% |
256,927
-164,273
| -39% | -$1.58M |
|
|
AENZ
2159
DELISTED
Aenza S.A.A.
AENZ
| $2.26M | ﹤0.01% |
105,430
+55,597
| +112% | +$1.28M |
|
|
AXE
2160
DELISTED
Anixter International Inc
AXE
| $2.26M | ﹤0.01% |
27,900
+23,900
| +598% | +$1.73M |
|
2161
Banco Santander
SAN
$211B
| $2.24M | ﹤0.01% |
450,944
+203,238
| +82% | +$924K |
|
2162
Harte-Hanks
HHS
$31.9M
| $2.24M | ﹤0.01% |
148,190
+24,500
| +20% | +$371K |
|
|
TESO
2163
DELISTED
Tesco Corp
TESO
| $2.23M | ﹤0.01% |
270,900
-3,700
| -1% | -$29.3K |
|
2164
Peoples Financial Services
PFIS
$714M
| $2.23M | ﹤0.01% |
45,800
+30,159
| +193% | +$1.31M |
|
2165
Crown Crafts
CRWS
$30.7M
| $2.23M | ﹤0.01% |
287,500
+22,300
| +8% | +$200K |
|
2166
Brown & Brown
BRO
$23.6B
| $2.23M | ﹤0.01% |
99,200
-523,200
| -84% | -$10.6M |
|
|
INSY
2167
DELISTED
Insys Therapeutics, Inc.
INSY
| $2.22M | ﹤0.01% |
241,500
-23,000
| -9% | -$260K |
|
|
NXTM
2168
DELISTED
NxStage Medical Inc.
NXTM
| $2.22M | ﹤0.01% |
84,783
-166,200
| -66% | -$4.11M |
|
|
WG
2169
DELISTED
Willbros Group
WG
| $2.2M | ﹤0.01% |
678,800
-39,300
| -5% | -$90.8K |
|
|
NWY
2170
DELISTED
New York & Co Inc
NWY
| $2.2M | ﹤0.01% |
967,800
+52,600
| +6% | +$115K |
|
2171
DMC Global
BOOM
$155M
| $2.2M | ﹤0.01% |
138,568
+21,068
| +18% | +$283K |
|
2172
Agilysys
AGYS
$3.22B
| $2.19M | ﹤0.01% |
211,900
+10,800
| +5% | +$111K |
|
2173
IMAX
IMAX
$2.9B
| $2.19M | ﹤0.01% |
69,900
-189,700
| -73% | -$5.93M |
|
|
SRGA
2174
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $2.19M | ﹤0.01% |
22,473
+5,040
| +29% | +$462K |
|
|
MIXT
2175
DELISTED
MIX TELEMATICS LIMITED
MIXT
| $2.19M | ﹤0.01% |
353,800
+22,900
| +7% | +$142K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.